Access cutting-edge alzheimer's disease treatment through this clinical trial at a research site in Scottsdale. Study-provided care at no cost to qualified participants.
Access alzheimer's disease specialists in Scottsdale at no cost
This study follows strict safety protocols and ethical guidelines
All study-related alzheimer's disease treatment provided free
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucina
Sponsor: MapLight Therapeutics
Check if you qualify for this alzheimer's disease clinical trial in Scottsdale, AZ
If you're searching for alzheimer's disease treatment options in Scottsdale, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Scottsdale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.